Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
The U.S. Department of Justice files an antitrust lawsuit against Visa over debit card payments

The U.S. Department of Justice files an antitrust lawsuit against Visa over debit card payments

Bitget2024/09/25 05:25

On September 25th, the U.S. Department of Justice (DOJ) filed an antitrust lawsuit against payment giant Visa, accusing it of monopolizing debit card payments. On September 24th, a complaint submitted to the New York Federal Court stated that Visa used exclusive agreements and threats of penalties against suppliers to prevent competitors from infringing on its market share.

It is reported that Visa holds a 60% market share in the field of debit card transactions in the United States, with transaction fees alone generating $7 billion in revenue. The complaint also states that Visa uses its market size and corporate holdings to attract potential competitors to establish partnerships. It is said that this will be consistent with the allegations made by the DOJ, namely that even if substitutes enter the market, Visa's practices would lead to price increases for consumers.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.